Form 4: Enliven Therapeutics CEO Samuel Kintz Sells Shares Under 10b5-1 Trading Plan

Enliven Therapeutics' CEO, Samuel Kintz, sold 12,500 shares of common stock at an average price of $20.8256, according to a Form 4 filing with the SEC.

Summary

• On March 17, 2025, Samuel Kintz, the President and CEO of Enliven Therapeutics, sold 12,500 shares of common stock.
• The sale was executed at a weighted average price of $20.8256 per share, with individual transactions ranging from $20.09 to $21.04.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024.
• Following the transaction, Kintz directly owns no shares, but indirectly owns 990,392 shares through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The document is a neutral report of an insider stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider information being used.

Key Dates

Keywords

Form 4, Enliven Therapeutics, Samuel Kintz, ELVN, stock sale, Rule 10b5-1 plan, insider trading